Bernd Hauck joined the newly founded Clinical Vector Core at its inception to set up the manufacture of adeno-associated virus (AAV) and recombinant lentiviral vectors (rLV ) for gene therapy studies.

He later joined Spark Therapeutics, a Philadelphia biotechnology company created in 2013 by Children's Hospital of Philadelphia, to establish AAV vector production. Hauck transferred the manufacturing process for AAV2-hRPE65v2 from CHOP to Spark and led the manufacturing group through successful U.S. Food and Drug Administration and European Medicine Agency approval of Luxturna™(voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Hauck obtained his PhD in Genetics from the University of Hohenheim, Germany, and conducted his postdoctoral studies in the department of Hematology at CHOP studying AAV serotype 1 muscle tropism and AAV genome biology thereby developing vectors for gene therapy. He has published more than 15 articles in peer reviewed journals and is co-inventor on multiple patents related to gene therapy vector technology.